A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)


Kayikcioglu M., Tokgozoglu L., Yilmaz M., KAYNAR L. , Aktan M., Durmus R. B. , ...Daha Fazla

ATHEROSCLEROSIS, cilt.270, ss.42-48, 2018 (SCI İndekslerine Giren Dergi) identifier

Özet

Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival.